DAAs increase serum VEGF level: a rationale for tumour risk recurrence during anti-HCV treatment
Authors:
- R. VillaniRVR. Villani
- A. FacciorussoAFA. Facciorusso
- F. BellantiFBF. Bellanti
- R. TamborraRTR. Tamborra
- A. PiscazziAPA. Piscazzi
- M. LandriscinaMLM. Landriscina
- G. VendemialeGVG. Vendemiale
- G. ServiddioGSG. Serviddio
- 1 January 2017
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S735